EMBELINE E Drug Patent Profile
✉ Email this page to a colleague
When do Embeline E patents expire, and what generic alternatives are available?
Embeline E is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in EMBELINE E is clobetasol propionate. There is one drug master file entry for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Embeline E
A generic version of EMBELINE E was approved as clobetasol propionate by COSETTE PHARMS NC on February 16th, 1994.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for EMBELINE E?
- What are the global sales for EMBELINE E?
- What is Average Wholesale Price for EMBELINE E?
Summary for EMBELINE E
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Patent Applications: | 5,581 |
| DailyMed Link: | EMBELINE E at DailyMed |
US Patents and Regulatory Information for EMBELINE E
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | EMBELINE E | clobetasol propionate | CREAM;TOPICAL | 075325-001 | Dec 24, 1998 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
